AlloMap: Changing Medical Practice and Revenue-Pierre Cassigneul-03/06/2012 - 8:30am

Event Information
Event Topic: 
AlloMap: Changing Medical Practice and Revenue
Event Date: 
03/06/2012 - 8:30am
Event Location: 
Sunnyvale City Council Chambers, 456 West Olive Ave., Sunnyale, CA
Speaker Information
Event Speaker: 
Pierre Cassigneul
Event Speaker Title: 
CEO & President
Event Speaker Company: 
XDx
Event Speaker Bio: 

Pierre Cassigneul

Pierre Cassigneul is the president and chief executive officer for XDx. Mr. Cassigneul has more than 20 years of senior management experience in the healthcare and medical device industries, both in Europe and the United States, including the global launch of several successful high-tech products. He joined XDx from the consulting firm, Stone Bridge Management LLC, where he was an operating partner. Formerly, as the vice president of diabetes management at Becton Dickinson & Co, he oversaw completion of the product, clinical trials and regulatory submissions. Mr. Cassigneul has held top management positions at Bayer in the diabetes self-testing business unit, where he developed and launched a new patient-monitoring system; Ortho Diagnostic Systems (J&J) in the AIDS and hepatitis business unit, where he launched a complete line of blood screening products; and Abbott Laboratories in the diagnostic division, where he launched the first HIV test for screening the European blood supply. Mr. Cassigneul holds a management degree from the Ecole Superieure de Commerce de Reims, France.

Event Details
Cost: 
$0
Event Details: 

Founded in 2000, XDx, Inc. is a privately held molecular diagnostics company that pioneered the application of gene expression profiling technology in the areas of transplant medicine and autoimmunity. XDx developed and commercializedthe first gene expression profiling test for heart transplant management, AlloMapĀ® Molecular Expression Testing.

AlloMap offers physicians a non-invasive tool to aid in the management of acute transplant rejection in heart transplant patients. AlloMap has been commercially available since 2005 and was cleared by the FDA in 2008 as a Class II Medical Device. The clinical use of AlloMap is part of the recommended guidelines for the care of heart transplant patients issued by the International Society of Heart and Lung Transplantation.

The molecular expression technology developed and implemented by XDx in heart transplant patient management is currently being explored to assist with other diseases that involve the immune system.